Nafamostat mesilate treatment during open heart operation in immune thrombocytopenic purpura.
暂无分享，去创建一个
[1] R. Vasudevan,et al. Coronary artery bypass grafting in immune thrombocytopenic purpura. , 1997, The Annals of thoracic surgery.
[2] R. Colman,et al. Nafamostat Mesilate, a Broad Spectrum Protease Inhibitor, Modulates Platelet, Neutrophil and Contact Activation in Simulated Extracorporeal Circulation , 1996, Thrombosis and Haemostasis.
[3] L. Piro,et al. The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura. , 1993, Blood.
[4] Jubelirer Sj. Coronary artery bypass in two patients with immune thrombocytopenic purpura without preoperative splenectomy. , 1992 .
[5] H. Matsuda,et al. Clinical evaluation of a new synthetic protease inhibitor in open heart surgery. Effect on plasma serotonin and histamine release and blood conservation. , 1992, ASAIO journal (1992).
[6] Y. Sawada,et al. Combined coronary revascularization and splenectomy. , 1989, The Annals of thoracic surgery.
[7] W. van Oeveren,et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. , 1987, The Annals of thoracic surgery.
[8] J. Marõnas,et al. Mitral Valve Replacement and Splenectomy in a Patient with Chronic Idiopathic Thrombocytopenic Purpura , 1982, The Thoracic and cardiovascular surgeon.